Starling Oncology, Inc. (STLN)

Every figure this model derived for STLN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 3,614,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 41,094,000 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-06-30
current assets 128,990,000 AssetsCurrent 2026-06-30
current liabilities 94,939,000 LiabilitiesCurrent 2026-06-30
equity -24,914,000 StockholdersEquity 2026-06-30
interest expense 7,629,000 InterestExpenseNonoperating 2026-06-30
ocf 328,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 587,244,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 5,097,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up STLN on one particular measure came for.

RatioValue
cash operating margin-2.42
current ratio1.39
current ratio reported1.36
deferred revenue growth-2.93
dilution pct23.13
fcf margin-0.56
growth cv0.33
interest cover-3.42
operating margin-4.44
owner earnings margin-1.43
revenue growth38.38
revenue growth per share12.38
roic-148.22
rule of 4033.94
sbc pct revenue0.87

What to be careful about

What this model itself distrusts about STLN's figures. Written by the derivation as it ran, not added afterwards.